Recent studies have intriguingly shown that CD4+ CTL can directly kill tumors aberrantly expressing MHCII by recognizing neoantigens, new antigens encoded by mutated genes and expressed on cancer cells [50,51,52,53]. The gene discussed is CD4; the disease is cancer.